Defunct Company
Total Trials
15
As Lead Sponsor
13
As Collaborator
2
Total Enrollment
1,162
NCT00321412
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 31, 2006
Completion: Sep 30, 2008
NCT00583076
Safety and Efficacy of AST-120 in the Treatment of Pouchitis
Phase: Phase 2
Start: Feb 28, 2007
Completion: May 31, 2008
NCT00583531
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
Start: Mar 31, 2007
Completion: Dec 31, 2008
NCT00583128
Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome
Start: Aug 31, 2007
Completion: Jun 30, 2010
NCT00558038
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
Start: Sep 30, 2007
Completion: Jun 30, 2009
NCT00587275
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
Start: Oct 31, 2007
Completion: Jun 30, 2008
NCT00867698
AST-120 Used to Treat Mild Hepatic Encephalopathy
Start: Mar 31, 2009
NCT01548690
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Role: Collaborator
Start: Jun 30, 2012
Completion: Feb 23, 2017
NCT01966419
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Start: Jan 7, 2014
Completion: Dec 29, 2016
NCT03159390
Metabolism of Ornithine Phenylacetate
Phase: N/A
Start: Feb 3, 2015
Completion: Apr 30, 2015
NCT03846843
OCR002-SP103 - Oral Immediate Release Study
Phase: Phase 1
Start: Aug 15, 2016
Completion: Dec 31, 2017
NCT02914613
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
Phase: Phase 1/2
Start: Aug 24, 2016
Completion: May 16, 2017
NCT02914639
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
Start: Oct 5, 2016
Completion: Jun 26, 2017
NCT05409235
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
Start: Jul 29, 2022
Completion: Dec 29, 2023